Content
10/24/2023 Pittsburgh, PA USA
LyGenesis completed $19 million Series A Round funding. Investors include Prime Movers Lab (lead).
#Biotech  #Life Science  
About
LyGenesis is a biotechnology company with an organ regeneration technology platform enabling a patient’s lymph nodes to be used as bioreactors to regrow functioning ectopic organs. LyGenesis’ lead preclinical program is focused on liver regeneration for patients with end stage liver disease. Other therapeutic targets for organ regeneration include the thymus, pancreas, and kidney.
Startup
LyGenesis
https://www.lygenesis.com Claim Profile
Location:
Pittsburgh, PA USA
Sector:
Biotech
Life Science
Download StockFan App Ad
Stock market data, news and community, all integrated.
Features include real time stock quotes, interactive charts, technical signals, institutional & insider ownerships, stock screener, ETF rankings, SEC filings, press releases, videos, earnings calendar, social media posts, group chats.